178 related articles for article (PubMed ID: 19581933)
21. Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey.
Crudden C; Song D; Cismas S; Trocmé E; Pasca S; Calin GA; Girnita A; Girnita L
Cells; 2019 Oct; 8(10):. PubMed ID: 31600876
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of β-elemene via targeting the phosphorylation of insulin receptor.
Wu D; Lv D; Zhang T; Guo L; Ma F; Zhang C; Lv G; Huang L
Endocr Relat Cancer; 2019 Feb; 26(2):187-199. PubMed ID: 30422809
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells.
Liu R; Tang W; Han X; Geng R; Wang C; Zhang Z
Oncol Lett; 2018 Nov; 16(5):5983-5991. PubMed ID: 30333869
[TBL] [Abstract][Full Text] [Related]
24. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
25. Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Aiken R; Axelson M; Harmenberg J; Klockare M; Larsson O; Wassberg C
Oncotarget; 2017 Oct; 8(46):81501-81510. PubMed ID: 29113409
[TBL] [Abstract][Full Text] [Related]
26. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
[TBL] [Abstract][Full Text] [Related]
27. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights.
Li H; Batth IS; Qu X; Xu L; Song N; Wang R; Liu Y
Mol Cancer; 2017 Jan; 16(1):6. PubMed ID: 28137302
[TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of IGF1R/IR PET ligand [
Prabhakaran J; Dewey SL; McClure R; Simpson NR; Tantawy MN; Mann JJ; Pham W; Kumar JSD
Bioorg Med Chem Lett; 2017 Feb; 27(4):941-943. PubMed ID: 28094184
[TBL] [Abstract][Full Text] [Related]
29. Fasting and Caloric Restriction in Cancer Prevention and Treatment.
Brandhorst S; Longo VD
Recent Results Cancer Res; 2016; 207():241-66. PubMed ID: 27557543
[TBL] [Abstract][Full Text] [Related]
30. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
[TBL] [Abstract][Full Text] [Related]
31. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
Ramalingam S; Ramamurthy VP; Njar VCO
J Steroid Biochem Mol Biol; 2017 Feb; 166():16-27. PubMed ID: 27481707
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways.
Werner H; Sarfstein R; LeRoith D; Bruchim I
Front Oncol; 2016; 6():159. PubMed ID: 27446805
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-1 signaling in renal cell carcinoma.
Tracz AF; Szczylik C; Porta C; Czarnecka AM
BMC Cancer; 2016 Jul; 16():453. PubMed ID: 27405474
[TBL] [Abstract][Full Text] [Related]
34. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E
Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151
[TBL] [Abstract][Full Text] [Related]
35. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
37. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.
Hawsawi Y; Humphries MP; Wright A; Berwick A; Shires M; Al-Kharobi H; El-Gendy R; Jove M; Twelves C; Speirs V; Beattie J
Oncotarget; 2016 May; 7(22):32129-43. PubMed ID: 27050076
[TBL] [Abstract][Full Text] [Related]
38. Cathepsin Inhibition Prevents Autophagic Protein Turnover and Downregulates Insulin Growth Factor-1 Receptor-Mediated Signaling in Neuroblastoma.
Soori M; Lu G; Mason RW
J Pharmacol Exp Ther; 2016 Feb; 356(2):375-86. PubMed ID: 26660229
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL.
Bartram I; Erben U; Ortiz-Tanchez J; Blunert K; Schlee C; Neumann M; Heesch S; Baldus CD
BMC Cancer; 2015 Oct; 15():663. PubMed ID: 26450156
[TBL] [Abstract][Full Text] [Related]
40. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
